GENFIT
Last · Paris€8.14+0.31 (+3.96%)live · yahoo · 3h ago
Vol 237.2K ≈ 1.93M
MA10MA20MA50
Market cap€407.3M50.0M sh
P/E · TTM-4.0fwd 87.1 · eps -2.04 · loss
Beta1.19vs S&P 500
Div yield0.00%annual · TTM
52w range
€3.40€15.48
Volume237.2Ksession
Issuer
Legal nameGENFIT
HQEurope (EU)
ListingEU GNFT
ISINFR0004163111
SectorHealthcare
IndustryBiotechnology & Medical Research
CurrencyEUR
Entity registrylei:969500XPWN2DMZQA5X73
Websitewww.genfit.com
Employees188
AddressGenfit SA Parc Eurasante 59120, Loos +33 3 20 16 40 00
| Revenue | €70.9M |
|---|---|
| Operating income | €3.3M |
| Net income | €1.5M |
| Free cash flow | €14.6M |
| Operating margin | 4.6% |
| Net margin | 2.1% |
| Return on equity | 2.2% |
| Period | 2024 |
Loading chart…
OpenFilings analyst
Our analyst
ANNUAL · 2026-04-03
From latest ANNUAL · 2026-04-03
- Operating Cf Burn
- Net Margin Sharply Negative
Red flags
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -120.9%
Press & signals
- GlobeNewswire
GENFIT Reports First-Half 2026 Financial Results and Provides Corporate Update
- GlobeNewswire
GENFIT Advances Nangibotide in Phase 2 Clinical Investigation in ACLF
- GlobeNewswire
GENFIT to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris
The rest of this company's wire — with summaries and source links — is part of Pro.
See plansDocuments
FormReporting forFiledFlags
Showing 5 of 305 filings